Livagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala (KEDA), studied in laboratory settings as part of the short regulatory peptide research literature. This overview covers its structure, synthesis, and in vitro study applications only.

Structure and Synthesis

At four amino acids, livagen is produced by standard solid-phase peptide synthesis, purified by preparative reversed-phase HPLC, and confirmed by mass spectrometry. Its small size and charged residues make it a useful model compound for studying short-peptide stability and analytical behavior in vitro.

In Vitro Study Applications

• Cell culture models examining short-peptide interactions with cellular systems
• Gene-expression and molecular pathway readouts in controlled laboratory experiments
• Stability and degradation studies of short peptides in buffer and media conditions
• Analytical method development, where a well-characterized tetrapeptide serves as a reference analyte

Analytical Notes

Researchers typically confirm identity by mass spectrometry, purity by RP-HPLC, and net content by amino acid analysis before use in sensitive assays, since peptide quality directly affects reproducibility.

References

Khavinson et al., published literature on short synthetic peptides in experimental models; standard solid-phase synthesis and peptide characterization literature.

This article is for laboratory research education only. All products referenced are not for human consumption / research use only. No medical, therapeutic, dosing, or efficacy information is provided or implied.